[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

3 Dividend Aristocrats With Soaring Profits That Wall Street Says to Buy Now

A long dividend streak is impressive, but it means more when the business behind it is still growing.

When investors look for income, it is easy to focus only on dividend yield. But a high yield alone does not always mean a strong investment. The better question is whether the company can support that dividend with real earnings, a healthy payout ratio, and a business model that can keep moving forward.

Fundamentals

See More
  • Market Capitalization, $K 535,629,824
  • Shares Outstanding, K 2,407,217
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 23,115 M
  • EBITDA $ 30,618 M
  • 60-Month Beta 0.27
  • Price/Sales 5.74
  • Price/Cash Flow 15.91
  • Price/Book 6.66

Options Overview Details

View History
  • Implied Volatility 21.14% (-0.02%)
  • Historical Volatility 15.57%
  • IV Percentile 69%
  • IV Rank 49.91%
  • IV High 29.89% on 03/27/26
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 7) 4.34 (1.96%)
  • Put/Call Vol Ratio 0.56
  • Today's Volume 21,228
  • Volume Avg (30-Day) 21,880
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 350,639
  • Open Int (30-Day) 351,916
  • Expected Range 216.98 to 225.66

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.83
  • Number of Estimates 8
  • High Estimate $2.88
  • Low Estimate $2.69
  • Prior Year $2.77
  • Growth Rate Est. (year over year) +2.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
220.63 +0.31%
on 05/07/26
244.20 -9.37%
on 04/09/26
-19.98 (-8.28%)
since 04/08/26
3-Month
220.63 +0.31%
on 05/07/26
251.71 -12.07%
on 03/02/26
-18.67 (-7.78%)
since 02/06/26
52-Week
146.12 +51.47%
on 05/14/25
251.71 -12.07%
on 03/02/26
+65.66 (+42.18%)
since 05/08/25

Most Recent Stories

More News
3 Dividend Aristocrats With Soaring Profits That Wall Street Says to Buy Now

3 Dividend Aristocrats with strong profit growth, safe payout ratios, decades of raises, and Buy-rated Wall Street support.

IBM : 229.76 (+0.06%)
PPG : 109.61 (+0.62%)
JNJ : 221.32 (-0.53%)
Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

Generation Fine launches after global survey finds nearly 4 in 5 patients living with major depressive disorder don't believe antidepressants will help them reach remission

JNJ : 221.32 (-0.53%)
As American Water Works Hikes Its Dividend, Consider Buying AWK Stock in May

The broader investment case rests on AWK's 19-year dividend growth streak, a 5-year average dividend growth rate of about 9%, and a pending merger with Essential Utilities that would make it the largest...

AWK : 125.05 (-0.91%)
$SPX : 7,398.93 (+0.84%)
JNJ : 221.32 (-0.53%)
PH : 878.83 (-0.68%)
$DOWI : 49,609.16 (+0.02%)
SO : 91.80 (-0.68%)
Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

JNJ-4804 demonstrated highest rates of clinical and endoscopic outcomes compared to golimumab and guselkumab in patients with ulcerative colitis or Crohn's disease who have had inadequate response to two...

JNJ : 221.32 (-0.53%)
Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

TREMFYA ® demonstrated significantly higher rates of combined fistula remission – complete external closure of draining fistulas and absence of fluid collection on MRI – compared to...

JNJ : 221.32 (-0.53%)
Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

Study results represent a critical milestone for the investigational OTTAVA ™ Robotic Surgical System Data demonstrates feasibility of novel...

JNJ : 221.32 (-0.53%)
Are Wall Street Analysts Bullish on Johnson & Johnson Stock?

Johnson & Johnson has outperformed the broader market over the past year, and Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

XLV : 143.49 (-0.85%)
$SPX : 7,398.93 (+0.84%)
JNJ : 221.32 (-0.53%)
CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

CAPLYTA ® ranked highest among FDA-approved adjunctive therapies across four measures of efficacy, based on indirect comparisons from placebo plus antidepressant therapy-controlled trials...

JNJ : 221.32 (-0.53%)
Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced the appointment of Ryan Koors to Vice President, Investor Relations, effective May 7, 2026. Mr. Koors will report to Johnson & Johnson’s...

JNJ : 221.32 (-0.53%)
3 Dependable Dividend Stocks for Beginners

If you're just getting started or just want to identify a few of the bluest dividend blue chips, check out our look at a few top dividend stocks.

MSFT : 415.12 (-1.34%)
PRU : 100.81 (+1.38%)
AVGO : 430.00 (+4.23%)
JNJ : 221.32 (-0.53%)
AMD : 455.19 (+11.44%)
ADBE : 253.04 (-1.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 225.27
2nd Resistance Point 224.32
1st Resistance Point 222.82
Last Price 221.32
1st Support Level 220.37
2nd Support Level 219.42
3rd Support Level 217.92

See More

52-Week High 251.71
Last Price 221.32
Fibonacci 61.8% 211.37
Fibonacci 50% 198.91
Fibonacci 38.2% 186.45
52-Week Low 146.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.